Baird Adjusts Price Target on Zimmer Biomet to $104 From $92, Maintains Neutral Rating

Baird has raised its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $104 from $92, while maintaining a Neutral rating on the stock. This adjustment comes amidst a flurry of analyst activity, with several other firms also updating their price targets for the medical equipment company. The article also provides a brief company profile and lists recent news and financial data for Zimmer Biomet.